<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03939078</url>
  </required_header>
  <id_info>
    <org_study_id>CO2 laser</org_study_id>
    <nct_id>NCT03939078</nct_id>
  </id_info>
  <brief_title>CO2 Laser in the Treatment of the GSM - (Genitourinary Syndrome of Menopause) Genitourinary Syndrome of Menopause</brief_title>
  <official_title>Fractional Ablative CO2 Laser in the Treatment of the Genitourinary Syndrome of Menopause</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal Fluminense</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alma Lasers</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Federal Fluminense</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Menopause is a woman's hormonal status one year after her ovulatory failure, when the
      decrease of circulating estrogen levels leads to a group of symptoms named Genitourinary
      Syndrome of Menopause (GSM), such as: vaginal dryness, dyspareunia, dysuria, epithelial
      fragility with recurrent bleedings, loss of genital elasticity and pH alterations causing
      recurrent infections. The CO2 laser is a fractional ablative source of light, capable of
      inducing neocollagenesis within the skin, reversing atrophies, increasing blood supply and
      reorganizing the architectural structure of the treated epithelium. Recent studies in the
      laser field show great improvement of the SGM, with satisfying results in female's sexual
      disfunction. Nevertheless, there is still a lack of studies that show, at the same time, the
      improvement in both patient's subjective reports and objective measurements, such as
      cytology, histology and immunohistochemistry. This study aims to thoroughly analyze the
      benefits of the CO2 laser in the treatment of the GMS, comparing the improvement found in
      questionnaires to the results of cytology, histology and immunohistochemistry for collagen I
      and III from vaginal biopsies before and after the laser treatment. Therefore, fourteen women
      after menopause complaining of symptoms of the GSM were selected from the ambulatory of the
      Hospital Universitário Antônio Pedro. The patients will be submitted to three CO2
      intravaginal laser (Femilift®), with a 30-days interval between them. Biopsies of the vaginal
      wall will be taken one month before the start and one month after the end of the laser
      sessions, and material will be sent to histology, cytology and immunohistochemistry analysis.
      Results obtained will be compared to the patients' reports, in order to evaluate subjective
      and objective improvement due to the treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 5, 2018</start_date>
  <completion_date type="Anticipated">December 5, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 5, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reversion of vaginal atrophy</measure>
    <time_frame>1 month after the last (3rd) laser section</time_frame>
    <description>Reversion of vaginal atrophy by the laser stimulation, with increasing layers of epithelial cells, increased collagen deposition and improvement in vascularization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in urinary incontinence</measure>
    <time_frame>1 month after the third and last laser section</time_frame>
    <description>Improvement in urine involuntary loss, the so called stress incontinence</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Menopause</condition>
  <condition>Vaginal Atrophy</condition>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Vaginal Laser Intervention</arm_group_label>
    <description>Patients will be submitted to vaginal biopsy before and after three laser sections, and therefore will be their own comparative group to see the improvement associated with the laser effects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CO2 fractional ablative laser</intervention_name>
    <description>3 intravaginal fractional ablative CO2 laser sections, with one month interval between them.</description>
    <arm_group_label>Vaginal Laser Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Volunteer women from 40 to 70 years, healthy and with regular gynecologist follow up, not
        willing or not eligible to take hormones to treat the GSM, experimenting difficulties in
        their sexual life and their daily routine, due to vaginal atrophy and urinary incontinence.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women from 40 to 70 years old;

          -  Post- menopausa (at least one year after cessation of periods);

          -  Experimenting any symptom related to the Genitourinary Syndrome of Menopause (GSM),
             such as: vaginal dryness, dyspareunia, urinary incontinence, dysuria, recurrent
             urinary infections;

          -  Regular follow up in gynecologist, with recent normal pap smear.

        Exclusion Criteria:

          -  The volunteers must not be under any treatment for this syndrome;

          -  Volunteers cannot be using hormones or any vaginal treatment;

          -  Volunteers cannot have previous history of vaginal / uterine cancer;

          -  Volunteers cannot have previous surgery for urinary incontinence;

          -  Uterine prolapse;

          -  Recent altered pap smear.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario Antonio Pedro</name>
      <address>
        <city>Niteroi</city>
        <state>Rio De Janeiro</state>
        <zip>24033-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>DiBonaventura M, Luo X, Moffatt M, Bushmakin AG, Kumar M, Bobula J. The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe. J Womens Health (Larchmt). 2015 Sep;24(9):713-22. doi: 10.1089/jwh.2014.5177. Epub 2015 Jul 22.</citation>
    <PMID>26199981</PMID>
  </reference>
  <reference>
    <citation>Keil K. Urogenital atrophy: diagnosis, sequelae, and management. Curr Womens Health Rep. 2002 Aug;2(4):305-11.</citation>
    <PMID>12150759</PMID>
  </reference>
  <reference>
    <citation>Palacios S, Castelo-Branco C, Currie H, Mijatovic V, Nappi RE, Simon J, Rees M. Update on management of genitourinary syndrome of menopause: A practical guide. Maturitas. 2015 Nov;82(3):308-13. doi: 10.1016/j.maturitas.2015.07.020. Epub 2015 Jul 26. Review.</citation>
    <PMID>26261035</PMID>
  </reference>
  <reference>
    <citation>Zerbinati N, Serati M, Origoni M, Candiani M, Iannitti T, Salvatore S, Marotta F, Calligaro A. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci. 2015 Jan;30(1):429-36. doi: 10.1007/s10103-014-1677-2. Epub 2014 Nov 20.</citation>
    <PMID>25410301</PMID>
  </reference>
  <reference>
    <citation>Lindahl SH. Reviewing the options for local estrogen treatment of vaginal atrophy. Int J Womens Health. 2014 Mar 13;6:307-12. doi: 10.2147/IJWH.S52555. eCollection 2014. Review.</citation>
    <PMID>24648775</PMID>
  </reference>
  <reference>
    <citation>Perino A, Calligaro A, Forlani F, Tiberio C, Cucinella G, Svelato A, Saitta S, Calagna G. Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser. Maturitas. 2015 Mar;80(3):296-301. doi: 10.1016/j.maturitas.2014.12.006. Epub 2014 Dec 25.</citation>
    <PMID>25596815</PMID>
  </reference>
  <reference>
    <citation>Hutchinson-Colas J, Segal S. Genitourinary syndrome of menopause and the use of laser therapy. Maturitas. 2015 Dec;82(4):342-5. doi: 10.1016/j.maturitas.2015.08.001. Epub 2015 Aug 12. Review.</citation>
    <PMID>26323234</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal Fluminense</investigator_affiliation>
    <investigator_full_name>Maria Claudia Almeida Issa</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>menopause</keyword>
  <keyword>vaginal atrophy</keyword>
  <keyword>urinary incontinence</keyword>
  <keyword>CO2 laser</keyword>
  <keyword>fractional laser</keyword>
  <keyword>dyspareunia</keyword>
  <keyword>vaginal dryness</keyword>
  <keyword>vaginal lubrication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

